BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:YH32364 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of YH32364\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06975410-2814@assetmemo.bio
DTSTAMP:20261121T005453Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:YH32364: Phase 1/2 readout est. (NCT06975410)
DESCRIPTION:YH32364\, phase 1/2.\nStudy: Clinical Trial of YH32364 in Patie
 nts With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/yh32364#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06975410
URL:https://assetmemo.bio/drug/yh32364#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
